Pharmaceutical maker Gilead: Remdesivir drug reduces the risk of death among the severely ill by 62%

Pharmaceutical maker Gilead Sciences reported that its remdesivir drug for the treatment of the corona virus reduces the risk of death among the severely ill by 62%. The company stated that the new findings will be accompanied by further studies later.
"We are expanding our understanding of the benefit of the drug, and to further the use of the drug, we are sharing information with the research world and updating researchers as quickly as possible," the company noted.
At the end of June, it was announced that Gilead had announced it would charge the US government and other developed countries $ 390 for a vial of the drug. This is a $ 2,340 fee for five-day care.
According to a statement released at the end of June, Gilead will offer this price to developed countries around the world, in order to produce a uniform price model that will prevent the need to conduct individual negotiations with each country, which may delay the drug delivery process.
Ramadsibir is one of the first drugs to be used for the treatment of corona. In May, she received emergency approval from the US government, after an experiment found that the drug accelerated the recovery and discharge process of hospitalized patients in four days. Meanwhile, it has been reported that Giliad has signed an agreement with the US administration that will only supply him with the drug at least until October. There is a shortage of medicine in Israel and the question is whether the government led by Netanyahu will ask the US administration for a certain amount of the only medicine today that has the approval of the Directorate of Drugs and Food for the treatment of roccona.